For instance, BTYNB, a selective inhibitor of IGF2BP1, reduces IGF2BP1 protein expression and retards ovarian cancer growth by impairing interactions between IGF2BP1 and c-MYC or E2F1 mRNA [273]. The gene discussed is IGF2BP1; the disease is ovarian carcinoma.